ArticleJournal of muscle research and cell motility2026
Role of integrin αvβ5 receptor and microglia in delayed-onset muscle soreness in mice.
Article in Journal of muscle research and cell motility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Delayed-onset muscle soreness (DOMS) is characterized by muscle pain, stiffness, and tenderness following intense or unaccustomed exercise. In humans, symptoms typically arise 6-72 h post-exercise. This study investigated a novel mechanism underlying DOMS, focusing on the involvement of the irisin receptor integrin αvβ5 and spinal microglia in its development. Male C57BL/6 mice were subjected to a DOMS model induced by an acute aerobic exercise protocol, and nociceptive thresholds were assessed using the von Frey filament test. The role of spinal integrin αvβ5 was evaluated via intrathecal administration of the antagonist cilengitide, given both prior to exercise and 24 h post-exercise. To assess irisin's nociceptive effects, it was also administered intrathecally. Additionally, minocycline, a microglial inhibitor, was administered before irisin to determine microglial involvement. An in vitro assay evaluated microglial activation by irisin via flow cytometry. Pro- and anti-inflammatory cytokines were quantified by ELISA. Cilengitide reversed exercise-induced DOMS and reduced spinal pro-inflammatory cytokines. Irisin induced nociception, which was attenuated by minocycline. Irisin also activated microglia in vitro, increasing pro-inflammatory cytokine production. These findings suggest integrin αvβ5 and spinal microglia play critical roles in DOMS pathogenesis, with irisin and pro-inflammatory cytokines as key mediators.
Indexed as
Identifiers
42909689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.